Pleural Mesothelioma
Mesothelioma Surgery
Xavier Bichat Medical School, Paris, France
Post-Doctoral Research Fellow, Harvard Medical School
Surgical Oncology
Procedures Offered:
Extended Resections for Thoracic Malignancies
Minimally Invasive Thoracic Surgery
Conditions Treated:
Lung Cancer
Mediastinal Tumors
Pleural Mesothelioma
Rare Lung Diseases
Thoracic Sarcomas

About Dr. Loic Lang-Lazdunski

Although he is recognized as one of the world’s foremost authorities on mesothelioma surgery, Dr. Loic Lang-Lazdunski believes it takes a specialty center with multidisciplinary expertise to treat the cancer optimally.

“It’s the collaboration with experts in all the fields that will make us successful with these patients,” he said. “It’s the personalization of the treatment and the extensive experience from pulmonologists, surgeons, oncologists, pathologists, anesthetists and nurses on staff.”

Lang-Lazdunski has been a professor and a general and thoracic surgeon at Genolier Clinic in Switzerland since 2023. He twice served as the chief medical officer at the London Mesothelioma Clinic from 2021-2023 and from 2014-2020.

Lang-Lazdunski has served at several mesothelioma treatment centers. He moved to Quebec in 2020 to head the Pleural Mesothelioma Program at the Quebec Heart and Lung Institute at Laval University. Prior to moving to Canada, he spent 12 years as a consultant thoracic surgeon at Guy’s and St. Thomas’ NHS Foundation Trust in London. He became a professor of thoracic surgery at King’s College, London, with a chair in mesothelioma in 2012.

In 2022, Lang-Lazdunski published research showing that cancer-directed surgery, systemic chemotherapy and prophylactic radiotherapy may provide a significant survival benefit in selected mesothelioma patients.

His extensive and successful experience in treating mesothelioma has led to an international following. Lang-Lazdunski collaborates with prominent mesothelioma specialists worldwide and has contributed to several landmark studies that have helped improve both the treatment and prognosis of pleural mesothelioma.

He is a member of several respected medical groups, including the International Mesothelioma Interest Group, the European Association for Cardio-Thoracic Surgery, the European Society of Thoracic Surgeons and the International Association for the Study of Lung Cancer.

Dr. Lang-Lazdunski’s Role as Medical Reviewer on

Lang-Lazdunski is among the world’s most respected pleural mesothelioma surgeons. His skill, expertise and international surgical experience qualify him to review pages and author articles for His contributions ensure our pleural mesothelioma content remains current, consistent and medically correct.

He regularly contributes to the European Lung Cancer Congress, World Conference on Lung Cancer, American Society of Clinical Oncology, European Society of Thoracic Surgeons and The Mesothelioma Center at, the nation’s most trusted mesothelioma resource.

Specialist consultation with a patient
Find a Mesothelioma Cancer Center

Access top mesothelioma cancer centers that have experience treating this rare disease.

Get Help Now

Specialties of Dr. Loic Lang-Lazdunski

  • Lung cancer surgery and biology
  • Mesothelioma surgery
  • Minimally invasive thoracic surgery
  • Mediastinal tumors
  • Pleural mesothelioma
  • Rare lung diseases
  • Thoracic sarcomas

Experience and Medical Education

  • Genolier Clinic
  • University Institute of Cardiology and Pneumology of Quebec
  • The London Mesothelioma Clinic
  • King’s College London
  • Guy’s & St Thomas Hospital
  • Percy Military Hospital
  • Hôpital Européen Georges Pompidou
  • University of Paris (Residency)
  • Harvard Medical School (Research Fellow)
  • Xavier Bichat Medical School (M.D.)

Awards and Recognition

  • Laureate of the National Academy of Medicine, France, 2002
  • Silver Medal from the Faculty of Medicine of Paris, France, 1996

Mesothelioma Clinical Trials Under Dr. Loic Lang-Lazdunski

  • Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS) was an open-label, randomized, controlled trial.
  • Extrapleural pneumonectomy versus no extrapleural pneumonectomy for patients with malignant pleural mesothelioma. This trial included clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomized feasibility study.
  • Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy investigated the safety and effectiveness of the drug.
  • Protocol for PIT was a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention.

Dr. Loic Lang-Lazdunski’s Publications

  • Lang-Lazdunski, L. (2018). Malignant pleural mesothelioma: some progress, but still a long way from cure.
  • Lang-Lazdunski, L. (2015). Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience.
  • Bille, A. (2013). Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication.
  • Lang-Lazdunski, L. (2012). Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma.
  • Medical-Surgical Encyclopedia
  • Textbook of Pleural Disease
  • Oxford Textbook of Respiratory Critical Care
  • Thorax Wounds and Trauma
  • Thoracic Videosurgery Techniques
  • Textbook of Congenital and Acquired Diseases of the Aorta